Alpine Global Management LLC Sells 129,624 Shares of Mural Oncology plc (NASDAQ:MURA)

Alpine Global Management LLC lowered its holdings in Mural Oncology plc (NASDAQ:MURA) by 61.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 80,964 shares of the company’s stock after selling 129,624 shares during the period. Alpine Global Management LLC owned approximately 0.48% of Mural Oncology worth $261,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Jane Street Group LLC bought a new position in Mural Oncology during the fourth quarter valued at approximately $68,000. Two Sigma Advisers LP bought a new stake in shares of Mural Oncology in the 4th quarter valued at about $84,000. Bridgeway Capital Management LLC bought a new position in Mural Oncology during the 4th quarter worth approximately $94,000. Northern Trust Corp increased its stake in Mural Oncology by 22.0% in the 4th quarter. Northern Trust Corp now owns 39,966 shares of the company’s stock worth $129,000 after purchasing an additional 7,197 shares during the period. Finally, Virtu Financial LLC purchased a new stake in shares of Mural Oncology during the fourth quarter valued at approximately $129,000. Hedge funds and other institutional investors own 80.21% of the company’s stock.

Mural Oncology Price Performance

Shares of Mural Oncology stock opened at $2.75 on Friday. Mural Oncology plc has a 1 year low of $0.95 and a 1 year high of $4.74. The company has a 50-day moving average of $2.28 and a 200 day moving average of $3.22. The firm has a market cap of $47.49 million, a price-to-earnings ratio of -0.30 and a beta of 3.91.

Mural Oncology (NASDAQ:MURA) last announced its earnings results on Wednesday, May 14th. The company reported ($1.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.12) by $0.19. On average, equities analysts anticipate that Mural Oncology plc will post -7.54 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on MURA shares. Raymond James lowered shares of Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 target price for the company. in a report on Tuesday, March 25th. Jones Trading reiterated a “hold” rating on shares of Mural Oncology in a research report on Tuesday, March 25th. Morgan Stanley cut Mural Oncology from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, March 25th. Finally, HC Wainwright dropped their price target on Mural Oncology from $18.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, March 26th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $13.00.

Mural Oncology Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.